Research progress on relationship between Coronavirus Disease 2019 and diabetes

MENG Yiqun; ZHANG Zhenwen

doi:10.7619/jcmp.20222272

Journal of Clinical Medicine in Practice > 2023 > 27(1): 140-144, 148. > DOI: 10.7619/jcmp.20222272

MENG Yiqun, ZHANG Zhenwen. Research progress on relationship between Coronavirus Disease 2019 and diabetes[J]. Journal of Clinical Medicine in Practice, 2023, 27(1): 140-144, 148. DOI: 10.7619/jcmp.20222272

Citation:

PDF (656 KB)

Research progress on relationship between Coronavirus Disease 2019 and diabetes

MENG Yiqun,
ZHANG Zhenwen^,

Department of Endocrinology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu, 225001

More Information

Received Date: July 24, 2022
Available Online: February 01, 2023

Graphical Abstract

Abstract

Abstract

Diabetes is associated with the high risk of death of severe Coronavirus Disease 2019 (COVID-19), and the management levels of glycosylated hemoglobin (HbA1c) and blood glucose are also associated with the adverse outcomes of COVID-19. The proportion of newly diagnosed diabetes patients with COVID-19 is higher than that normal people, and severe patients may even cause diabetes ketoacidosis (DKA). In clinic, appropriate hypoglycemic regimen can improve the prognosis of COVID-19 patients. The relationship between COVID-19 and diabetes is complex. The article aimed to elaborate relevant studies and explore their relationship.

FullText(HTML)

References (58)

References

[1]	HARTMANN-BOYCE J, REES K, PERRING J C, et al. Erratum. risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: asystematic review of reviews[J]. Diabetes Care, 2022, 45(6): 1489. doi: 10.2337/dc22-er06
[2]	HOLMAN N, KNIGHTON P, KAR P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study[J]. Lancet Diabetes Endocrinol, 2020, 8(10): 823-833. doi: 10.1016/S2213-8587(20)30271-0
[3]	APICELLA M, CAMPOPIANOM C, MANTUANO M, et al. COVID-19 in people with diabetes: understanding the reasons for worse outcomes[J]. Lancet Diabetes Endocrinol, 2020, 8(9): 782-792. doi: 10.1016/S2213-8587(20)30238-2
[4]	GREGGE W, SOPHIEAM K, WELDEGIORGIS M. Diabetes and COVID-19: population impact 18 months into the pandemic[J]. Diabetes Care, 2021, 44(9): 1916-1923. doi: 10.2337/dci21-0001
[5]	SINGHA K, SINGH R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19[J]. Diabetes Res Clin Pract, 2020, 167: 108382. doi: 10.1016/j.diabres.2020.108382
[6]	CHEEY J, NGS J H, YEOH E. Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus[J]. Diabetes Res Clin Pract, 2020, 164: 108166. doi: 10.1016/j.diabres.2020.108166
[7]	MEHTA P, MCAULEYD F, BROWN M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229): 1033-1034. doi: 10.1016/S0140-6736(20)30628-0
[8]	GUAN W J, NI Z Y, HU Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720.
[9]	ZHANG Y, CUI Y H, SHEN M X, et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: a retrospective cohort study[J]. Diabetes Res Clin Pract, 2020, 165: 108227. doi: 10.1016/j.diabres.2020.108227
[10]	IZCOVICH A, RAGUSAM A, TORTOSA F, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review[J]. PLoS One, 2020, 15(11): e0241955. doi: 10.1371/journal.pone.0241955
[11]	ZHANGH B, PENNINGERJ M, LIY M, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target[J]. Intensive Care Med, 2020, 46(4): 586-590. doi: 10.1007/s00134-020-05985-9
[12]	CHEEMAA K, KAUR P, FADEL A, et al. Integrated datasets of proteomic and metabolomic biomarkers to predict its impacts on comorbidities of type 2 diabetes mellitus[J]. Diabetes Metab Syndr Obes, 2020, 13: 2409-2431. doi: 10.2147/DMSO.S244432
[13]	CARIOU B, HADJADJ S, WARGNY M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study[J]. Diabetologia, 2020, 63(8): 1500-1515. doi: 10.1007/s00125-020-05180-x
[14]	WU J F, HUANG J Q, ZHU G C, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study[J]. BMJ Open Diabetes Res Care, 2020, 8(1): e001476. doi: 10.1136/bmjdrc-2020-001476
[15]	MEMON S S, BISWASDA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management[J]. Cureus, 2022, 14(11): e31895.
[16]	NORRIS T, RAZIEH C, YATES T, et al. Admission blood glucose level and its association with cardiovascular and renal complications in patients hospitalized with COVID-19[J]. Diabetes Care, 2022, 45(5): 1132-1140. doi: 10.2337/dc21-1709
[17]	SATHISH T, KAPOOR N, CAO Y T, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis[J]. Diabetes Obes Metab, 2021, 23(3): 870-874. doi: 10.1111/dom.14269
[18]	AL-ALY Z, XIE Y, BOWE B. High-dimensional characterization of post-acute sequelae of COVID-19[J]. Nature, 2021, 594(7862): 259-264. doi: 10.1038/s41586-021-03553-9
[19]	WANDERP L, LOWY E, BESTEL A, et al. The incidence of diabetes among 2, 777, 768 veterans with and without recent SARS-CoV-2 infection[J]. Diabetes Care, 2022, 45(4): 782-788. doi: 10.2337/dc21-1686
[20]	BARRETTC E, KOYAMAA K, ALVAREZ P, et al. Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged < 18 years-United States, March 1, 2020-June 28, 2021[J]. MMWR Morb Mortal Wkly Rep, 2022, 71(2): 59-65. doi: 10.15585/mmwr.mm7102e2
[21]	KHUNTI K, DEL PRATO S, MATHIEU C, et al. COVID-19, hyperglycemia, and new-onset diabetes[J]. Diabetes Care, 2021, 44(12): 2645-2655. doi: 10.2337/dc21-1318
[22]	GAZZARUSO C, COPPOLA A, GALLOTTI P, et al. Comment on khunti et al. COVID-19, hyperglycemia, and new-onset diabetes. diabetes care 2021; 44: 2645-2655[J]. Diabetes Care, 2022, 45(2): e45. doi: 10.2337/dc21-2241
[23]	YAZDANPANAH N, REZAEI N. Autoimmune complications of COVID-19[J]. J Med Virol, 2022, 94(1): 54-62. doi: 10.1002/jmv.27292
[24]	LUID T W, LEEC H, CHOWW S, et al. Insights from a prospective follow-up of thyroid function and autoimmunity among COVID-19 survivors[J]. Endocrinol Metab (Seoul), 2021, 36(3): 582-589. doi: 10.3803/EnM.2021.983
[25]	MURUGANA K, ALZAHRANIA S. SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease[J]. Endocrine, 2021, 73(2): 243-254. doi: 10.1007/s12020-021-02770-6
[26]	CHEN N S, ZHOU M, DONG X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study[J]. Lancet, 2020, 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7
[27]	ZHOU P, YANGX L, WANGX G, et al. Addendum: a pneumonia outbreak associated with a new coronavirus of probable bat origin[J]. Nature, 2020, 588(7836): E6. doi: 10.1038/s41586-020-2951-z
[28]	LAN J, GE J W, YU J F, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature, 2020, 581(7807): 215-220. doi: 10.1038/s41586-020-2180-5
[29]	FIGNANI D, LICATA G, BRUSCO N, et al. SARS-CoV-2 receptor angiotensin I-converting enzyme type 2 (ACE2) is expressed in human pancreatic β-cells and in the human pancreas microvasculature[J]. Front Endocrinol (Lausanne), 2020, 11: 596898. doi: 10.3389/fendo.2020.596898
[30]	COATE K C, CHA J, SHRESTHA S, et al. SARS-CoV-2 cell entry factors ACE2 and TMPRSS2 are expressed in the microvasculature and ducts of human pancreas but are not enriched in βcells[J]. Cell Metab, 2020, 32(6): 1028-1040, e4. doi: 10.1016/j.cmet.2020.11.006
[31]	KUSMARTSEVA I, WU W T, SYED F, et al. Expression of SARS-CoV-2 entry factors in the pancreas of normal organ donors and individuals with COVID-19[J]. Cell Metab, 2020, 32(6): 1041-1051, e6. doi: 10.1016/j.cmet.2020.11.005
[32]	TANEERA J, EL-HUNEIDI W, HAMAD M, et al. Expression profile of SARS-CoV-2 host receptors in human pancreatic islets revealed upregulation of ACE2 in diabetic donors[J]. Biology (Basel), 2020, 9(8): 215.
[33]	HOLLSTEIN T, SCHULTED M, SCHULZ J, et al. Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report[J]. Nat Metab, 2020, 2(10): 1021-1024. doi: 10.1038/s42255-020-00281-8
[34]	CARLSSONP O, BERNE C, JANSSON L. Angiotensin Ⅱ and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats[J]. Diabetologia, 1998, 41(2): 127-133. doi: 10.1007/s001250050880
[35]	AKASHM S H, REHMAN K, LIAQAT A. Tumor necrosis factor-alpha: role in development of insulin resistance and pathogenesis of type 2 diabetes mellitus[J]. J Cell Biochem, 2018, 119(1): 105-110. doi: 10.1002/jcb.26174
[36]	XU E, PEREIRAM M A, KARAKASILIOTI I, et al. Temporal and tissue-specific requirements for T-lymphocyte IL-6 signalling in obesity-associated inflammation and insulin resistance[J]. Nat Commun, 2017, 8: 14803. doi: 10.1038/ncomms14803
[37]	KOBASHI C, ASAMIZU S, ISHIKI M, et al. Inhibitory effect of IL-8 on insulin action in human adipocytes via MAP kinase pathway[J]. J Inflamm (Lond), 2009, 6: 25. doi: 10.1186/1476-9255-6-25
[38]	MUNIANGI-MUHITU H, AKALESTOU E, SALEM V, et al. Covid-19 and diabetes: acomplex bidirectional relationship[J]. Front Endocrinol (Lausanne), 2020, 11: 582936. doi: 10.3389/fendo.2020.582936
[39]	NAYAR M, VARGHESE C, KANWAR A, et al. SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study[J]. Gut, 2022, 71(7): 1444-1447. doi: 10.1136/gutjnl-2021-326218
[40]	MISRA S, BARRON E, VAMOS E, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study[J]. Lancet Diabetes Endocrinol, 2021, 9(10): 671-680. doi: 10.1016/S2213-8587(21)00208-4
[41]	ZHONGV W, JUHAERI J, MAYER-DAVISE J. Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998-2013: aretrospective cohort study[J]. Diabetes Care, 2018, 41(9): 1870-1877. doi: 10.2337/dc17-1583
[42]	LIJ Y, WANGX F, CHEN J, et al. COVID-19 infection may cause ketosis and ketoacidosis[J]. Diabetes ObesMetab, 2020, 22(10): 1935-1941.
[43]	KUCHAYM S, REDDYP K, GAGNEJA S, et al. Short term follow-up of patients presenting with acute onset diabetes and diabetic ketoacidosis during an episode of COVID-19[J]. Diabetes Metab Syndr, 2020, 14(6): 2039-2041. doi: 10.1016/j.dsx.2020.10.015
[44]	RUBINO F, AMIELS A, ZIMMET P, et al. New-onset diabetes in covid-19[J]. N Engl J Med, 2020, 383(8): 789-790. doi: 10.1056/NEJMc2018688
[45]	CROUSEA B, GRIMES T, LI P, et al. Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes[J]. Front Endocrinol (Lausanne), 2020, 11: 600439.
[46]	HARIYANTOT I, KURNIAWAN A. Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection[J]. Obes Med, 2020, 19: 100290. doi: 10.1016/j.obmed.2020.100290
[47]	KAHKOSKAA R, ABRAHAMSENT J, ALEXANDERG C, et al. Association between glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor use and COVID-19 outcomes[J]. Diabetes Care, 2021, 44(7): 1564-1572. doi: 10.2337/dc21-0065
[48]	DRUCKERD J. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications[J]. Endocr Rev, 2020, 41(3): bnaa011. doi: 10.1210/endrev/bnaa011
[49]	GAO Q, ZHANGW J, LIT T, et al. Interrelationship between 2019-nCov receptor DPP4 and diabetes mellitus targets based on protein interaction network[J]. Sci Rep, 2022, 12(1): 188. doi: 10.1038/s41598-021-03912-6
[50]	RYANP M, CAPLICEN M. Is adipose tissue a reservoir for viral spread, immune activation, and cytokine amplification in coronavirus disease 2019[J]. Obesity (Silver Spring), 2020, 28(7): 1191-1194. doi: 10.1002/oby.22843
[51]	VITALER J, VALTISY K, MCDONNELLM E, et al. Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT2 inhibitors[J]. AACE Clin Case Rep, 2021, 7(1): 10-13. doi: 10.1016/j.aace.2020.11.019
[52]	DASS B, BECK A, HOLMES C, et al. Euglycemic DKA (euDKA) as a presentation of COVID-19[J]. Clin Case Rep, 2021, 9(1): 395-398. doi: 10.1002/ccr3.3540
[53]	SARDU C, D'ONOFRIO N, BALESTRIERIM L, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control[J]. Diabetes Care, 2020, 43(7): 1408-1415. doi: 10.2337/dc20-0723
[54]	KATULANDA P, DISSANAYAKEH A, RANATHUNGA I, et al. Prevention and management of COVID-19 among patients with diabetes: an appraisal of the literature[J]. Diabetologia, 2020, 63(8): 1440-1452. doi: 10.1007/s00125-020-05164-x
[55]	ALHAZZANI W, MØLLERM H, ARABIY M, et al. Surviving Sepsiscampaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)[J]. Crit Care Med, 2020, 48(6): e440-e469. doi: 10.1097/CCM.0000000000004363
[56]	MAW X, RANX W. The management of blood glucose should be emphasized in the treatment of COVID-19[J]. Sichuan Da Xue Xue Bao Yi Xue Ban, 2020, 51(2): 146-150.
[57]	BERTONA M, PRENCIPE N, GIORDANO R, et al. Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view[J]. J Endocrinol Invest, 2021, 44(4): 873-875. doi: 10.1007/s40618-020-01325-2
[58]	WANG A H, ZHAO W B, XU Z R, et al. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed[J]. Diabetes Res Clin Pract, 2020, 162: 108118. doi: 10.1016/j.diabres.2020.108118

Cited By

Cited by

Periodical cited type(0)

Other cited types(1)

Get Citation

PDF

XML

Article views (271) PDF downloads (43) Cited by(1)

Turn off MathJax

Article Contents

Abstract

References

Research progress on relationship between Coronavirus Disease 2019 and diabetes

Abstract

References

Cited by

Periodical cited type(0)

Other cited types(1)

Catalog

Export File

Citation

Format

Content